[go: up one dir, main page]

BRPI0409580A - compostos de quinazolina - Google Patents

compostos de quinazolina

Info

Publication number
BRPI0409580A
BRPI0409580A BRPI0409580-4A BRPI0409580A BRPI0409580A BR PI0409580 A BRPI0409580 A BR PI0409580A BR PI0409580 A BRPI0409580 A BR PI0409580A BR PI0409580 A BRPI0409580 A BR PI0409580A
Authority
BR
Brazil
Prior art keywords
compounds
quinazoline compounds
quinazoline
usable
report
Prior art date
Application number
BRPI0409580-4A
Other languages
English (en)
Inventor
James Patrick Dunn
David Michael Goldstein
Christoph Martin Stahl
Teresa Alejandra Trejo-Martin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0409580A publication Critical patent/BRPI0409580A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTOS DE QUINAZOLINA". A presente invenção refere-se a compostos de fórmula, em que R4, R5, R6, R7, Q, m e n são como definidos no relatório. Os compostos são utilizáveis como inibidores de p38 quinase, e assim, podem ser usados para tratamento de distúrbio mediado por p38.
BRPI0409580-4A 2003-04-16 2004-04-08 compostos de quinazolina BRPI0409580A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46346703P 2003-04-16 2003-04-16
PCT/EP2004/003779 WO2004092144A2 (en) 2003-04-16 2004-04-08 Quinazoline compounds useful as p38 kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0409580A true BRPI0409580A (pt) 2006-04-18

Family

ID=33300076

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409580-4A BRPI0409580A (pt) 2003-04-16 2004-04-08 compostos de quinazolina

Country Status (14)

Country Link
US (2) US7238698B2 (pt)
EP (1) EP1620408A2 (pt)
JP (1) JP2006523638A (pt)
KR (1) KR100812586B1 (pt)
CN (1) CN1774425A (pt)
AR (1) AR044516A1 (pt)
AU (1) AU2004230209A1 (pt)
BR (1) BRPI0409580A (pt)
CA (1) CA2522522A1 (pt)
CL (1) CL2004000806A1 (pt)
MX (1) MXPA05011103A (pt)
RU (1) RU2356896C2 (pt)
TW (1) TW200423937A (pt)
WO (1) WO2004092144A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0409580A (pt) * 2003-04-16 2006-04-18 Hoffmann La Roche compostos de quinazolina
CN1882345A (zh) * 2003-10-16 2006-12-20 希龙公司 作为raf激酶抑制剂以治疗癌症的2,6－二取代的喹唑啉、喹喔啉、喹啉和异喹啉
WO2006118256A1 (ja) * 2005-04-28 2006-11-09 Kyowa Hakko Kogyo Co., Ltd. 2-アミノキナゾリン誘導体
WO2006137421A1 (ja) * 2005-06-21 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. 局所投与剤
FR2888749B1 (fr) * 2005-07-19 2007-10-12 Biocodex Composition pharmaceutique destinee a la prevention ou au traitement des oedemes cerebraux
FR2888748B1 (fr) * 2005-07-19 2007-10-12 Biocodex Composes neuroprotecteurs et compositions pharmaceutiques les comprenant
JPWO2008050808A1 (ja) * 2006-10-24 2010-02-25 協和発酵キリン株式会社 ２−アミノキナゾリン誘導体
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
EP2226315A4 (en) 2007-12-28 2012-01-25 Carna Biosciences Inc 2-aminoquinazoline DERIVATIVE
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
ES2929077T3 (es) 2011-02-07 2022-11-24 Biogen Ma Inc Agentes moduladores de S1P
SG11201407336PA (en) 2012-05-25 2015-03-30 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
KR102788773B1 (ko) 2012-12-21 2025-03-28 얀센 바이오파마, 인코퍼레이트. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체
CA2907243C (en) 2013-03-15 2021-12-28 Celgene Avilomics Research, Inc. Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
SG11201507478VA (en) 2013-03-15 2015-10-29 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
JP7012152B2 (ja) 2017-10-05 2022-02-10 フルクラム セラピューティクス，インコーポレイテッド Ｆｓｈｄの治療のためにｄｕｘ４および下流遺伝子発現を低減するｐ３８キナーゼ阻害剤
EP3560615A1 (de) 2018-04-27 2019-10-30 Primetals Technologies Austria GmbH Walzgeruest

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1024908A (en) * 1963-11-04 1966-04-06 Monsanto Chemicals Pyrimidine derivatives
GB1199768A (en) 1966-10-31 1970-07-22 Pfizer & Co C Nitrogen Heterocycles and process for their preparation
US4672116A (en) 1985-12-20 1987-06-09 Ortho Pharmaceutical Corporation Substituted 5,6-dialkoxyquinazoline derivatives
JPS6438315A (en) * 1987-08-05 1989-02-08 Okura Yusoki Co Ltd Transfer sorting device
JPH073725B2 (ja) * 1987-08-22 1995-01-18 パイオニア株式会社 マルチデイスクプレ−ヤ
US5084463A (en) 1989-12-11 1992-01-28 American Home Products Corporation N-quinolinyl alkyl-substituted 1-aryloxy-2-propanolamine and propylamine derivatives possessing class III antiarrhythmic activity
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
DK0556310T3 (da) 1990-11-06 1995-08-21 Pfizer Quinazolinderivater til forhøjelse af antitumoraktivitet
IL108630A0 (en) * 1993-02-18 1994-05-30 Fmc Corp Insecticidal substituted 2,4-diaminoquinazolines
EP0817775B1 (en) * 1995-03-30 2001-09-12 Pfizer Inc. Quinazoline derivatives
US20020061879A1 (en) 1996-02-02 2002-05-23 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
ES2384551T3 (es) 1997-03-05 2012-07-06 Sugen, Inc. Formulaciones para agentes farmacéuticos hidrófobos
JPH11209350A (ja) * 1998-01-26 1999-08-03 Eisai Co Ltd 含窒素複素環誘導体およびその医薬
US6313294B1 (en) 1998-02-04 2001-11-06 Development Center For Biotechnology Process for preparing amides
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
AU1071301A (en) 1999-11-01 2001-05-14 Eli Lilly And Company Pharmaceutical compounds
EP1235815A1 (en) * 1999-11-22 2002-09-04 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
EP1110552A1 (en) 1999-12-22 2001-06-27 Aventis Pharma S.A. Use of a compound with affinity for the mitochondrial benzodiazepine receptor in cancer therapy
AU2001245401A1 (en) 2000-03-01 2001-09-12 Sumitomo Pharmaceuticals Company, Limited Hydrazones and analogs as cholesterol lowering agents
HUP0300721A3 (en) 2000-07-26 2006-02-28 Smithkline Beecham Plc Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity, process for producing them, pharmaceutical compositions containing them and use thereof
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
EP1389209B1 (en) 2001-04-24 2009-04-08 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
BRPI0409580A (pt) * 2003-04-16 2006-04-18 Hoffmann La Roche compostos de quinazolina

Also Published As

Publication number Publication date
JP2006523638A (ja) 2006-10-19
KR20050122264A (ko) 2005-12-28
KR100812586B1 (ko) 2008-03-13
CN1774425A (zh) 2006-05-17
TW200423937A (en) 2004-11-16
WO2004092144A3 (en) 2005-03-24
RU2005135339A (ru) 2006-08-10
US20040209904A1 (en) 2004-10-21
US20070167471A1 (en) 2007-07-19
MXPA05011103A (es) 2005-12-12
WO2004092144A2 (en) 2004-10-28
CA2522522A1 (en) 2004-10-28
US7456185B2 (en) 2008-11-25
US7238698B2 (en) 2007-07-03
AR044516A1 (es) 2005-09-14
RU2356896C2 (ru) 2009-05-27
AU2004230209A1 (en) 2004-10-28
CL2004000806A1 (es) 2005-02-04
EP1620408A2 (en) 2006-02-01

Similar Documents

Publication Publication Date Title
BRPI0409580A (pt) compostos de quinazolina
DK1836201T3 (da) Pyrrolidininhibitorer af IAP
DE60315146D1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
EA201000563A1 (ru) Триазолпиридиновые ингибиторы 11-бета- гидроксистероид - дегидрогеназы типа i
IL189194A (en) Benzimidazoles are conserved as kinase inhibitors and their use in the preparation of cancer drugs
CY1114554T1 (el) Ινδαζολια, βενζοτριαζολια και ν-αναλογα αυτων ως αναστολεις p38 κινασης
DE60319364D1 (de) Substituierte pyrroline als kinase inhibitoren
ATE348616T1 (de) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
ATE353217T1 (de) 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
EA201070238A1 (ru) Соединения пиримидина
DE60323749D1 (de) Substituierte pyrroline als kinase inhibitoren
BR0308787A (pt) Inibidores de metaloproteinase de n-substituìdos-heteroarilóxi-aril-espiro-pirimidina- 2,4,6-triona
ATE517896T1 (de) P38-kinase-inhibitoren
EA201100689A1 (ru) N-сульфонилпирролы и их применение в качестве ингибиторов гистондезацетилазы
MX2007005408A (es) Compuestos de aminoquinazolinas.
NO20071127L (no) Triazoloftalaziner
ATE461923T1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
EA201000618A1 (ru) 5-цианотиенопиридины для лечения опухолей
BRPI0407913A (pt) antagonistas receptores de ccr-3
BRPI0416030A (pt) pirido-7-pirimidin-7-onas substituìdas com hidroxialquila
NO20081292L (no) Pentasykliske kinaseinhibitorer
CY1111432T1 (el) Τετραϋδροκινολινες για χρηση ως διαμορφωτες της μιτοτικης κινητικης πρωτεϊνης eg5
TW200600499A (en) Novel amido-substituted hydroxy-6-phenylphenanthridines
DE602004005881D1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
BRPI0409405A (pt) compostos 7-aza-quinazolina substituìdos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.